EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunotherapy with nebulized pattern recognition receptor agonists restores severe immune paralysis and improves outcomes in mice with influenza-associated pulmonary aspergillosis

Jezreel Pantaleón García iD, Sebastian Wurster iD, Nathaniel D Albert, Uddalak Bharadwaj, Keerthi Bhoda, Vikram K Kulkarni, Mbaya Ntita, Paris Rodríguez Carstens, Madeleine Burch-Eapen, Daniela Covarrubias López, Jania Foncerrada Lizaola, Katherine E Larsen und 5 weitere

mBio · 2025

DOI: 10.1128/mbio.04061-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2025. Verfasst von Jezreel Pantaleón García und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Pulmonary Aspergillosis, Receptors, Pattern Recognition, Immunotherapy, Orthomyxoviridae Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Gilead Global Pharma, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Influenza-associated pulmonary aspergillosis (IAPA) is a potentially deadly superinfection in patients with influenza pneumonia, especially those with severe disease, underlying immunosuppression, corticosteroid therapy, or requiring intensive care support. Given the high mortality of IAPA, adjunct immunomodulatory strategies remain a critical unmet need. Previously, the desensitization of pattern recognition pathways has been described as a hallmark of IAPA pathogenesis and a predictor of mortality in IAPA patients. Therefore, we studied the impact of nebulized Toll-like receptor 2/6/9 agonists Pam2 CSK4 (Pam2) and CpG oligodeoxynucleotides (ODNs) on infection outcomes and pulmonary immunopathology in a corticosteroid-immunosuppressed murine IAPA model. Mice with IAPA receiving mock therapy showed rapidly progressing disease and a paralyzed immune response to secondary Aspergillus fumigatus infection. Nebulized Pam2ODN was well tolerated and significantly prolonged event-free survival. Specifically, dual-dose Pam2ODN therapy before and after A. fumigatus infection led to 81% survival and full recovery of all survivors. Additionally, transcriptional analysis of lung tissue homogenates revealed induction of pattern recognition receptor signaling and several key effector cytokine pathways after Pam2ODN therapy. Moreover, transcriptional and flow cytometric analyses suggested increased frequencies of macrophages, natural killer cells, and T cells in the lungs of Pam2ODN-treated mice. Collectively, immunomodulatory treatment with nebulized Pam2ODN strongly improved morbidity and mortality outcomes and alleviated paralyzed antifungal immunity in an otherwise lethal IAPA model. These findings suggest that Pam2ODN might be a promising candidate for locally delivered immunomodulatory therapy to improve outcomes of virus-associated mold infections such as IAPA. IMPORTANCE The COVID-19 pandemic has highlighted the significant healthcare burden, morbidity, and mortality caused by secondary fungal pneumonias. Given the heightened prevalence of severe viral pneumonias, such as influenza, and poor outcomes of secondary mold pneumonias, adjunct immunotherapies are needed to prevent and treat secondary infections. We herein demonstrate severely paralyzed immunity to secondary Aspergillus fumigatus infection in a corticosteroid-immunosuppressed mouse model of influenza-associated pulmonary aspergillosis (IAPA), partially due to dysregulated pathogen-sensing pathways. To overcome immune paralysis and IAPA progression, we used a dyad of nebulized immunomodulators (Toll-like receptor agonists). Nebulized immunotherapy significantly improved morbidity and mortality compared to mock therapy, increased frequencies of mature mononuclear phagocytes and natural killer cells in the lung, and stimulated antimicrobial signaling. Collectively, this proof-of-concept study demonstrates the feasibility and efficacy of locally delivered immunomodulatory therapy to alleviate virus-induced immune dysregulation in the lung and improve outcomes of post-viral mold pneumonias such as IAPA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary AspergillosisReceptors, Pattern RecognitionImmunotherapyOrthomyxoviridae InfectionsAnimalsMiceAspergillus fumigatusDisease Models, AnimalFemaleOligodeoxyribonucleotidesLungTreatment OutcomeMice, Inbred C57BLNebulizers and Vaporizers

Stichwörter der Autor:innen

animal modelsaspergillosiscytokinesepithelial pathogenesisimmunomodulationimmunotherapyinfluenzainnate immunity recognitionmacrophagespneumonia

Substanzen

Receptors, Pattern RecognitionOligodeoxyribonucleotidesCPG-oligonucleotide

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Jezreel Pantaleón García, Sebastian Wurster, Dimitrios P Kontoyiannis, Scott E Evans

Förderung

  • NHLBI NIH HHS
  • Gilead Global Pharma
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Pantaleón García, J., Wurster, S., Albert, N. D., Bharadwaj, U., Bhoda, K., Kulkarni, V. K., Ntita, M., Rodríguez Carstens, P., Burch-Eapen, M., Covarrubias López, D., Foncerrada Lizaola, J., Larsen, K. E., Matula, L. M., Moghaddam, S. J., Wang, Y., Kontoyiannis, D. P., & Evans, S. E. (2025). Immunotherapy with nebulized pattern recognition receptor agonists restores severe immune paralysis and improves outcomes in mice with influenza-associated pulmonary aspergillosis. mBio. https://doi.org/10.1128/mbio.04061-24

Vancouver

Pantaleón García J, Wurster S, Albert ND, Bharadwaj U, Bhoda K, Kulkarni VK, et al. Immunotherapy with nebulized pattern recognition receptor agonists restores severe immune paralysis and improves outcomes in mice with influenza-associated pulmonary aspergillosis. mBio. 2025. doi:10.1128/mbio.04061-24

BibTeX
@article{PantalenGarca2025,
  author = {Pantaleón García, Jezreel and Wurster, Sebastian and Albert, Nathaniel D and Bharadwaj, Uddalak and Bhoda, Keerthi and Kulkarni, Vikram K and Ntita, Mbaya and Rodríguez Carstens, Paris and Burch-Eapen, Madeleine and Covarrubias López, Daniela and Foncerrada Lizaola, Jania and Larsen, Katherine E and Matula, Lauren M and Moghaddam, Seyed J and Wang, Yongxing and Kontoyiannis, Dimitrios P and Evans, Scott E},
  title = {Immunotherapy with nebulized pattern recognition receptor agonists restores severe immune paralysis and improves outcomes in mice with influenza-associated pulmonary aspergillosis},
  journal = {mBio},
  year = {2025},
  doi = {10.1128/mbio.04061-24}
}
Kostenlos starten →